| EPC336 | Prospective health setting evaluation of two Point of care Tests for Syphilis and HIV (PoSH Study) for the diagnosis and treatment of syphilis during an infectious syphilis outbreak in Canada | E-poster | Facility-based HIV testing strategies |
| EPC337 | Associations between service readiness and PMTCT cascade effectiveness: a 2018 cross-sectional analysis from Manica province, Mozambique | E-poster | Facility-based HIV testing strategies |
| EPC338 | Use of an electronic adult HIV screening tool and HIV self-testing for improved targeted HIV testing in Zimbabwe | E-poster | Facility-based HIV testing strategies |
| EPC339 | Safe index testing as a high yielding HIV case identification strategy, the successful implementation by Oljabet Health Center, Laikipia, Kenya | E-poster | Facility-based HIV testing strategies |
| EPF047 | Effects of financial incentives for clinic attendance on economic well-being among adults initiating antiretroviral therapy in Tanzania: a three-arm randomized controlled trial | E-poster | Financial incentives, micro-finance and other economic approaches |
| EPE214 | Accelerate to the Finish: increasing sustainable financing for HIV responses in Asia-Pacific to achieve the 2030 targets | E-poster | Financing HIV within UHC frameworks |
| EPE215 | Balancing sustainability of Community Based Health Insurance (CBHI) and full coverage of vulnerable persons living with HIV / AIDS (PLWHA): a highway to improved maternal and child welfare | E-poster | Financing HIV within UHC frameworks |
| EPE216 | Enhancing the financing of HIV epidemiological control through health insurance integration: a catalyst for sustainability | E-poster | Financing HIV within UHC frameworks |
| EPE217 | Can Indonesia reach sustainable response in 2030? Analysis on National AIDS Spending Assessment in Indonesia 2019-2020 | E-poster | Financing HIV within UHC frameworks |
| OAE0305 | Variation in average unit prices (2020) of antiretroviral drugs in generic accessible low- and middle-income countries | Oral abstract session with live Q&A | Financing HIV, hepatitis and STI testing and drug access: The economics of generics and differential pricing structures |